DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

This is a prospective, multi-center, observational registry study to evaluate the association of DecisionDx-Melanoma GEP subclass with the use of SLNB and clinical outcomes. Eligible patients who have newly diagnosed invasive cutaneous melanoma, are being considered for the SLNB procedure and are having DecisionDx-Melanoma GEP testing as part of their clinical care will be asked to participate in the study. Information regarding GEP test result, SLNB procedure (discussion, consideration, and use), SLNB result (if performed) and clinical outcomes will be collected.

Inclusions/Exclusions: Newly dx (w/in 2 mo. Primary bx) w/cutaneous melanoma. No stage III or IV at dx.